In resectable NSCLC, neoadjuvant chemotherapy enhances antitumor immunity by recruiting T and B cells and promoting a shift toward cytotoxic and memory CD8+ and CD4+ helper T cells. This evidence concerns the gene CD4 and non-small cell lung carcinoma.